Loading organizations...

§ Private Profile · 386 Park Ave S Fl 5, New York City, New York, 10016, United States
Paloma Health is a technology company.
Paloma Health operates as a virtual clinic providing integrated care for hypothyroidism. Its digital platform offers at-home thyroid testing, virtual consultations with endocrinologists, and personalized treatment plans, including prescription management. This model delivers accessible, holistic digital healthcare solutions for managing thyroid conditions.
Founded in 2018 by Marina Tarasova and Guillaume Cohen-Skalli, Paloma Health emerged from the insight that millions, particularly women, lacked personalized, effective care for hypothyroidism within traditional systems. This observation drove them to establish a virtual clinic, empowering patients with direct access to specialized expertise for proactive health management.
The company serves individuals seeking expert thyroid health management, focusing on women navigating hypothyroidism and midlife changes. Paloma Health's vision is to transform chronic care by offering convenient access to specialized medical expertise. Its mission aims to redefine health management, fostering a patient-centric, digitally-enabled healthcare experience.
Paloma Health has raised $3.0M across 1 funding round.
Paloma Health has raised $3.0M in total across 1 funding round.
Paloma Health has raised $3.0M across 1 funding round. Most recently, it raised $3.0M Seed in November 2024.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Nov 1, 2024 | $3M Seed | — | Playfair Capital, Speedinvest, David Giampaolo | Announced |
Paloma Health has raised $3.0M in total across 1 funding round.
Paloma Health's investors include Playfair Capital, Speedinvest, David Giampaolo.
Paloma Health is a UK-based technology-enabled healthcare provider focused on redesigning NHS services to eliminate waiting lists, starting with children's autism assessments and expanding to ADHD, dementia, allergies, and dermatology.[1][2][3][4] It serves families facing long NHS delays by offering rapid, NHS-backed autism diagnoses within four weeks via the "Right to Choose" scheme, at no cost to patients, using process re-engineering, proprietary software, and AI to streamline care pathways and optimize clinician efficiency.[1][3][4] The company raised £2m in pre-seed funding in 2024 from Triple Point Ventures, Heal Capital, and angels, achieving provider accreditation, clinical team recruitment, and first patient deliveries in under six months from founding.[2][4] This demonstrates strong early growth momentum in tackling NHS backlogs through tech-infused service delivery rather than standalone software.[2][3]
Paloma Health was founded in November 2023 by Mark Jenkins (CEO) and Darshak Shah, both repeat healthcare entrepreneurs motivated by empathy for families enduring NHS wait times for autism assessments, which can stretch years and cause significant anxiety.[1][2][3] Jenkins draws parallels to process innovations in fintech like Monzo, applying similar rethinking to regulated healthcare without inventing new treatments but dramatically improving delivery.[3] Shah, co-founder of Newmedica (acquired by Specsavers in 2021, treating over 1 million in ophthalmology), and Jenkins, co-founder of Oviva (scaled digital therapeutics for obesity and diabetes across Europe), bring proven expertise from building tech-driven NHS providers.[1][2] Aoife Barron complements the team with her background in nutrition, dietetics, and user-centric healthcare solutions across the UK and Europe.[1] Pivotal early traction included gaining NHS provider status and treating first patients in under six months.[2]
(Note: Search results distinguish this UK autism/NHS-focused Paloma Health from a separate US thyroid care telehealth company at palomahealth.com, which offers unrelated services like hypothyroidism management.[5])
Paloma Health rides the shift from commoditized digital health SaaS "point solutions" to tech-enabled services that own outcomes, aligning incentives by guaranteeing results amid NHS crises like multi-year autism waits.[2][3][4] Timing is ideal: UK healthcare faces surging demand and backlogs post-pandemic, with policies like "Right to Choose" enabling disruption; process innovation mirrors successes in banking (Monzo) and beauty (Treatwell) by optimizing existing regulated systems.[3] Market forces favor it—rising autism/ADHD prevalence, clinician shortages, and investor rotation to asset-owning providers—positioning Paloma to capture share in community specialty care.[2][4] It influences the ecosystem by proving entrepreneurs can "earn the right to disrupt" via guaranteed outcomes, potentially scaling a playbook for NHS specialties and inspiring similar models globally.[2]
Paloma Health is poised to expand rapidly from autism to ADHD and beyond, leveraging its toolkit to tackle high-wait NHS areas like dementia, while refining AI for broader efficiency.[3][4] Trends like AI-driven admin reduction, outcome-based pricing, and NHS digital mandates will accelerate growth, though scaling regulated services demands navigating clinician recruitment and policy shifts.[2][4] Its influence may evolve from niche disruptor to category leader in tech-enabled NHS care, redefining provider models if it sustains launch speed—echoing founders' past exits and validating the bet on service ownership over software widgets.[2] This positions Paloma as a blueprint for process-led healthcare innovation amid systemic overload.